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Abstract 
 
Background/Aims: Network structure and individuals’ level of exposure to a pathogen can 
impact results from efficacy evaluation studies of interventions against infectious diseases. 
Heterogeneity in infection risk can cause randomized groups to increasingly differ as a trial 
progresses and as more high risk individuals become infected (described in prior work as the 
“frailty” phenomenon). Here we show the impact this phenomenon can have on an individually 
randomized trial of a leaky vaccine in which all participants are exchangeable a priori.  
Methods: We model a vaccine trial by generating a network of individuals grouped into 
communities, which are connected to a larger main population. We then simulate an epidemic, 
deterministically and with time-varying transmission rates in the main population, and 
stochastically in the communities. The disease natural history follows a Susceptible-Exposed-
Infectious-Recovered model. Simulation results are used to estimate vaccine efficacy (!"  ) with a 
Cox proportional hazards model.  
Results: We find downward bias in !"  associated with low connectivity between communities 
in the study population and high force of infection, even when all participants in the trial are 
exchangeable at the time of randomization. This phenomenon arises because the stochastic 
dynamics in such a setting randomly lead to community-level variation in the force of infection. 
Stratifying a Cox model by community alleviates this bias with no loss of power.  
Conclusion: Understanding and accounting for the impact of heterogeneous hazard rates can 
allow for more accurate estimates of !"	  in epidemic settings. 
Key words: vaccine trial, heterogeneous hazards, frailty, infectious disease, epidemics 
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Background/Aims 
 
Network structure and individuals’ degree of exposure to a pathogen can affect the efficacy 
analysis of interventions against infectious diseases. The “frailty” phenomenon, whereby 
heterogeneity in infection risk can cause randomized groups to increasingly differ as a trial 
progresses and more high-risk individuals become infected, has been well documented.1,2,3 Using 
a time-weighted hazard-ratio analysis, such as a Cox model, when heterogeneity in infection risk 
exists can induce bias in the vaccine efficacy estimate (!"  ) relative to the true direct vaccine 
efficacy (VE).4 The heterogeneity often occurs when a group of individuals has a higher risk of 
exposure compared to others a priori.3,5 Through simulation, we characterize the magnitude and 
direction of the bias of !"	  induced by heterogeneity of hazard rates in an individually 
randomized controlled trial of a leaky vaccine in which all participants are exchangeable at the 
beginning of the trial. We show that heterogeneous risk of infection arises due to the stochastic 
nature of epidemic dynamics in small populations, which leads individuals in some communities 
to experience higher infection risk than others. We then show that stratifying the analysis by 
community removes this bias without loss of power.  
 
Methods 
 
We model a vaccine trial by first generating a network of individuals grouped into communities, 
which are connected to a larger main population. Community size is uniformly distributed on a 
given range, with the mean community size and range as model inputs (Table 1). The average 
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number of connections individuals have with individuals in their own community and the 
average number of connections individuals have to those in other communities are each 
additional inputs of the model. Therefore, while individuals in the communities are not identical 
in terms of their exact number of connections, they are exchangeable in expected degree.  
We then simulate a deterministic epidemic in the main population with a time-varying 
transmission rate, and stochastic epidemics in each of the communities. The disease natural 
history follows a Susceptible-Exposed-Infectious-Recovered model. A connection between two 
people represents a daily contact between them, meaning all susceptible individuals have a daily 
probability of infection from each of their infectious neighbors of 1-e-β, where ß is the force of 
infection for that contact. Additionally, each individual experiences a daily external hazard of 
infection from the main population, which varies with the prevalence of infection in the main 
population (Table 1).  
7.5% of the population in the communities is enrolled into the trial, and individuals are 
randomized to either the vaccine or control groups. The vaccine is leaky, meaning that it reduces 
the probability of infection upon each exposure to an infectious individual;6,7 for those 
vaccinated, the daily probability of infection from their infectious contacts is 1-e-β(1-VE) where VE 
represents the direct leaky multiplicative vaccine efficacy input into the model. We estimate !"  
with a Cox proportional hazards model for time to symptom onset, with trial status (i.e. vaccine 
or control) as the explanatory variable. Individuals who are never infected are censored at the 
end of the study period. We estimate !"  both unstratified and stratified by community. Power is 
estimated by the proportion of simulations in which the p-value associated with the estimated !"  
is less than 0.05 and !" > 0  .
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We also estimate !"  from simulations of a trial of a vaccine with all-or-nothing effects, meaning 
it protects a certain percentage of people completely and others not at all, as well as from 
simulations varying different parameters, such as VE, the size of the communities, and the 
percent of each community enrolled into the trial. Additionally, we estimate !"  within subsets of 
the trial population, as subset analyses are often done, for example, within age groups or by sex. 
 
Results 
 
Using an unstratified Cox proportional hazards model to estimate !"  returns a downward bias in !"  relative to the input direct VE. As shown in Figure 1A, when input VE is set to 0.6, !"  from 
the unstratified analysis is less than 0.6. The bias increases with increases in R0 and decreases as 
communities become more connected to each other. A Cox model stratified by community 
alleviates the bias without reducing power (Figure 1B). This bias does not occur when the input 
VE is set to 1 or 0 (see Fig. S1 and Fig. S2). As expected, this bias also does not occur in a risk-
based analysis of a vaccine with all-or-nothing effects (see Fig. S3); however, a rate-based 
analysis of a vaccine with all-or-nothing effects returns an upward bias in !"  relative to the input 
direct VE (see Fig. S4).6,7,8  
We find that heterogeneity in hazard rates in an individually randomized vaccine trial with a 
leaky vaccine leads to a downward bias of !"  even when all individuals are exchangeable at the 
start of the trial. Although the simulated network structure does not assign anyone to be high risk 
a priori (i.e. everyone has the same initial risk of infection), heterogeneity in exposure still 
arises. Given the stochastic nature of epidemic dynamics, which includes introductions into the 
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trial population from the larger main population, certain communities have larger outbreaks 
while others escape infection entirely. Individuals in a community with a large outbreak 
experience more exposure to infection than those in which there is not a large outbreak. This 
heterogeneity in hazard is well known to create a downward bias in !"  2,6,7 because the 
individuals at greater risk of infection (here, the individuals in communities with larger 
epidemics) are depleted more rapidly from the control group than individuals at less risk of 
infection, making the average hazard in the control group more similar to that in the vaccine 
group over the course of the trial. When R0 is higher, individuals in communities with large 
outbreaks are exposed at an even higher rate than at lower levels of R0, further exacerbating 
these effects. As communities become more connected, the heterogeneity in exposure between 
communities decreases because large outbreaks spill over into neighboring communities, 
alleviating some of the bias.  
It is possible to show the source of the bias from the unstratified analysis in a causal directed 
acyclic graph (Figure 2). Let A be an indicator for vaccination status at baseline, Yt=1 an 
indicator for infection at an early time point, and Yt=2 be an indicator for infection at a second 
time point. Hazard ratio estimation at time = 2 conditions on those who were not infected at time 
= 1 (Yt=1 = 0), and the Cox model uses a weighted average of the time-specific hazard ratios.4 
Conditioning on Yt=1 opens a backdoor path from A to Yt=2, biasing the estimates of the effect of 
A on Yt=2.9 As shown in Figure 1A, the bias induced by heterogeneity in hazard rates across 
communities can be reduced by adjusting for community in a stratified Cox model analysis. This 
is because the backdoor path is blocked by conditioning on community. 
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We might expect the unstratified estimate to be biased due to a violation of the Cox model’s 
proportional hazards assumption. To evaluate this hypothesis, we conducted a weighted residuals 
test for violation of proportional hazards of the unstratified analysis,10 and then assessed the 
correlation between the resulting p-value and the difference between the stratified and 
unstratified !"  . This test did not provide a clear indication of bias in the unstratified estimate 
(correlation = 0.02, p-value = 0.80) and thus should not be used to determine if stratification is 
necessary to obtain an unbiased estimate. In settings with fairly disconnected communities where 
there is potential for heterogeneity in hazard rates, we recommend conducting a stratified 
analysis. Although an individual frailty model could also alleviate the downward bias, 
stratification alleviates the bias without reducing power discernibly for the baseline assumptions 
considered here. However, when the sample size is very small, for example in the case of a 
subset analysis, stratifying to reduce bias leads to a loss of power (see Fig. S5).   
Defining “community” for the purpose of stratification may present a challenge. While 
incorporating network structure into the design and analysis of trials is more often discussed in 
the context of cluster randomized trials, network surveys could also be used to identify the best 
unit for stratification in individually randomized trials.11 However, as shown in Figure 1, the 
downward bias of the unstratified analysis is noticeable only when the percentage of connections 
outside an individual’s community is less than 20%. In such a disconnected network, the 
communities will likely be distinct enough to identify, whereas in settings in which defining a 
community becomes more challenging, stratification will likely be unnecessary. 
Further analysis indicates that the bias is not dependent on the size of the communities or the 
number of people from each community enrolled into the trial. An analysis with larger 
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communities and a ten-fold increase in the number of people from each community enrolled into 
the trial also results in a downward bias in VE estimate, which is alleviated by stratification (see 
Fig. S6).  
 
Conclusion 
 
It is well known that heterogeneity leads to a bias in !".  3,5 However, it has previously only been 
discussed in the context of risk factor heterogeneity, either measured or unmeasured. Here we 
show that this bias can arise, and be alleviated, even when a priori heterogeneity does not exist.  
While these findings are specific to settings with fairly disconnected communities, understanding 
the potential sources of bias in analysis of vaccine trial results is essential for ensuring accurate 
estimates of !"  , which are important for the design of both vaccine trials and vaccine programs. 
Two vaccines that are equally efficacious may appear to have different !"	  if tested in different 
settings and analyzed without stratification, resulting in false conclusions about their relative 
efficacy. Furthermore, because !"	  is required for calculating the vaccine coverage needed in 
order to achieve herd immunity in a population, an underestimate could lead to unnecessarily 
expensive vaccination campaigns.  
Downward bias in the efficacy estimate for a leaky vaccine can occur in a population with a 
mixing structure other than complete random mixing, even when all trial participants are 
exchangeable a priori. Stratification by community, in a setting where mixing within 
communities is random, completely solves the problem with no loss of power. Stratified Cox 
models have previously been used in the analysis of vaccine efficacy studies, such as the 
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RTS,S/AS01 Malaria Vaccine individually randomized controlled trial, which stratified by study 
site.12 However, such stratification is not a universal practice and was not used in recent analyses 
of dengue or cholera vaccine trials.13,14 Stratification should be considered for future vaccine 
trials conducted in a large number of relatively disconnected centers, such as the planned Zika 
vaccine trials. 
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Figure 1. Unstratified vs stratified analyses: vaccine efficacy and power 
 
 
Caption: Figure 1A shows the vaccine efficacy estimates using stratified and unstratified 
analyses as the percentage of connections an individual has outside of their community and R0 
vary (compared to known vaccine efficacy of 0.60). Variance of the estimates range from 0.005-
0.162 for unstratified analyses and from 0.006-0.166 for stratified analyses, with lower variance 
for higher Ro. Figure 1B shows that the stratified analysis does not reduce power compared to 
the unstratified analysis.  
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Figure 2. Causal directed acyclic graph of bias in unstratified analysis 
Caption: Figure 2 shows the source of the bias in the unstratified analysis. Conditioning on 
those who were not infected at time = 1 in the analysis at time = 2 opens a backdoor path 
between A (vaccination status) and Yt=2 (outcome at time = 2), inducing bias.9 The dashed 
arrows indicate uncertainty regarding the relationship between A and Y, or the vaccine efficacy, 
which the trial aims to estimate. Note, only two times shown for simplicity. 
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Table 1. Parameters 
Parameter Meaning Value/range 
R0 Average number of secondary infections generated 
by an infected individual within the communities; 
function of force of infection (ß), infectious period 
and network structure (Appendix 1)  
1.00-1.50 
Latent period Latent period length (days) 9.715 
Mean 
(infectious) 
Mean infectious period length (days); gamma 
distributed with rate = 0.226 and shape = 1.13 
5.015 
VE Individual vaccine efficacy 0, 0.6, 1 
Ni Size of community i 100 (range 80-120) 
Num_ 
communities 
Number of communities in the network 200 
a Constant in calculation of importation rate into 
communities from main population  
• Mi = a * !"   where Mi is importation rate 
and Ni is the size of community i16 
(Appendix 2) 
0.025 
 
Within 
degree 
Average within-community degree17 7.5 – 15 
Between 
degree 
Average between-community degree17 0 – 7.5 
Trial size Average number of individuals enrolled 1,500 
Trial start 
day 
First day of enrollment, vaccination and start of 
follow-up, relative to the first day of the epidemic 
in the main population 
150 
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Trial length Length of follow-up after trial start (days) 140 
Appendix 1. R0 calculation18 !" = $*( '(' − 1)    !	 = 1 − ( '' + ß)+   
k = mean degree of the network 
k2 = mean square degree of the network !  = infectious period rate !  = infectious period shape 
ß = force of infection 
 
Appendix 2. Connection between main population and communities 
Fi*I = daily hazard of infection for an individual in community i from the main population 
where: 
• Fi = proportionality constant for the degree of contact between the main population and 
community i, with higher importation rate (M) for larger communities 
• I = number of infectious individuals in main population 
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